Marshall Wace LLP Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Marshall Wace LLP purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 127,097 shares of the company's stock, valued at approximately $10,754,000. Marshall Wace LLP owned 0.26% of Axsome Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. Barclays PLC lifted its holdings in Axsome Therapeutics by 279.6% during the 3rd quarter. Barclays PLC now owns 61,785 shares of the company's stock worth $5,552,000 after buying an additional 45,509 shares during the period. Franklin Resources Inc. lifted its stake in shares of Axsome Therapeutics by 47.5% in the third quarter. Franklin Resources Inc. now owns 160,534 shares of the company's stock worth $13,713,000 after acquiring an additional 51,696 shares during the period. JPMorgan Chase & Co. boosted its holdings in Axsome Therapeutics by 14.9% in the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after acquiring an additional 27,534 shares during the last quarter. Pallas Capital Advisors LLC acquired a new stake in Axsome Therapeutics during the 4th quarter valued at approximately $2,237,000. Finally, Flower City Capital bought a new position in Axsome Therapeutics during the 4th quarter worth approximately $254,000. Institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Price Performance

AXSM stock opened at $103.00 on Tuesday. The company has a market capitalization of $5.02 billion, a P/E ratio of -17.20 and a beta of 0.88. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $139.13. The business has a 50-day simple moving average of $117.59 and a two-hundred day simple moving average of $102.65. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Research analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AXSM has been the topic of a number of analyst reports. Morgan Stanley upped their price objective on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Leerink Partners increased their price target on Axsome Therapeutics from $110.00 to $150.00 and gave the stock an "outperform" rating in a report on Monday, February 10th. Robert W. Baird boosted their price objective on Axsome Therapeutics from $132.00 to $160.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $153.00 target price on shares of Axsome Therapeutics in a research note on Wednesday, February 19th. Finally, Mizuho lifted their target price on Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Axsome Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $169.80.

Insider Activity

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now owns 42,187 shares in the company, valued at approximately $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 22.40% of the stock is currently owned by corporate insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.